Anlon Healthcare Approves Financials, Acquisitions, and Share Capital Increase

Anlon Healthcare Ltd's Board of Directors met on August 13, 2026, approving audited standalone and consolidated financial statements for FY26. Key decisions include the appointment of a director, regularization of an independent director, and appointment of an internal auditor. The company also approved a significant increase in authorized share capital from ₹110 Cr to ₹130 Cr, subject to shareholder approval. Furthermore, Anlon Healthcare will proceed with acquiring up to 44.94% of Apiqo Organics and 47.41% of Bizotic Lifescience through share swap agreements, involving the issuance of over 8.58 crore equity shares on a preferential basis.